Aridis Pharmaceuticals, Inc.
ARDS
$0.0001
$0.000.00%
| Weiss Ratings | ARDS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | ARDS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | ARDS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 107.56 | |||
| Price History | ARDS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -99.86% | |||
| 2-Year Total Return | -99.96% | |||
| 3-Year Total Return | -99.99% | |||
| 5-Year Total Return | -100.00% | |||
| 52-Week High % Change | -99.88% | |||
| 52-Week Low % Change | 9,900.00% | |||
| Price | ARDS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.08 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Jul 22, 2024 | |||
| 52-Week High Price (Date) | Jul 03, 2024 | |||
| Valuation | ARDS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 5.33K | |||
| Enterprise Value | 4.81M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.19 | |||
| Earnings Per Share Growth | -90.51% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.00 | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | 0.22 | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -13.86 | |||
| Enterprise Value/EBIT | -7.33 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ARDS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 37.43M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ARDS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 408 385 1742 | |||
| Address | 983 University Avenue Los Gatos, CA 95032 | |||
| Website | www.aridispharma.com | |||
| Country | United States | |||
| Year Founded | 2003 | |||
| Profitability | ARDS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -2.93% | |||
| Profit Margin | -5.10% | |||
| Management Effectiveness | ARDS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -4.40% | |||
| Return on Equity | -- | |||
| Income Statement | ARDS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 22.36M | |||
| Total Revenue (TTM) | 22.36M | |||
| Revenue Per Share | $0.60 | |||
| Gross Profit (TTM) | 5.21M | |||
| EBITDA (TTM) | -347.00K | |||
| EBIT (TTM) | -656.00K | |||
| Net Income (TTM) | -1.14M | |||
| Net Income Avl. to Common (TTM) | -1.14M | |||
| Total Revenue Growth (Q YOY) | 4.51% | |||
| Earnings Growth (Q YOY) | 98.99% | |||
| EPS Diluted (TTM) | -0.19 | |||
| EPS Diluted Growth (Q YOY) | 99.53% | |||
| Balance Sheet | ARDS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 35.00K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 4.11M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -11.80M | |||
| Current Ratio (Q) | 0.235 | |||
| Book Value Per Share (Q) | -$0.26 | |||
| Total Assets (Q) | 6.53M | |||
| Total Current Liabilities (Q) | 17.48M | |||
| Total Debt (Q) | 4.84M | |||
| Total Liabilities (Q) | 18.34M | |||
| Total Common Equity (Q) | -11.80M | |||
| Cash Flow | ARDS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -35.00K | |||
| Cash from Financing (TTM) | 15.32M | |||
| Net Change in Cash (TTM) | -2.60M | |||
| Levered Free Cash Flow (TTM) | -16.39M | |||
| Cash from Operations (TTM) | -17.89M | |||
